Credit Suisse’s Crescent Biopharma CBIO Stock Holding History

Credit Suisse’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-308	Closed	-$133K	–	4230
2019 Q3	$133K	Buy	308 +78	+34%	+$50.2K	﹤0.01%	3937
2019 Q2	$274K	Sell	230 -15	-6%	-$17.9K	﹤0.01%	3720
2019 Q1	$306K	Sell	245 -137	-36%	-$157K	﹤0.01%	3587
2018 Q4	$362K	Buy	382 +70	+22%	+$84.2K	﹤0.01%	3425
2018 Q3	$449K	Sell	312 -105	-25%	-$159K	﹤0.01%	3360
2018 Q2	$674K	Sell	417 -409	-50%	-$703K	﹤0.01%	3276
2018 Q1	$1.34M	Buy	826 +707	+594%	+$1.47M	﹤0.01%	2749
2017 Q4	$200K	Buy	+119	New	+$157K	﹤0.01%	3747
2017 Q3	–	Sell	-171	Closed	-$191K	–	4207
2017 Q2	$191K	Buy	+171	New	+$141K	﹤0.01%	3630
2014 Q3	–	Sell	-101	Closed	-$85K	–	4513
2014 Q2	$85K	Buy	+101	New	+$101K	﹤0.01%	4560

Other funds holding CBIO

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Credit Suisse's CBIO Position: Q4 2019 in Review

Credit Suisse sold out of Crescent Biopharma (CBIO) in Q4 2019, closing a stake of 308 shares — an estimated $133K sold.

Credit Suisse first reported a position in CBIO in Q2 2014 and held it in 10 quarters. The position peaked at $1.34M in Q1 2018. 78 funds tracked by Wall St. Rank hold CBIO as of Q4 2019.

Credit Suisse reported no remaining Crescent Biopharma position as of Q4 2019 after selling out during the quarter.
Credit Suisse sold 308 Crescent Biopharma shares in Q4 2019, an estimated $133K.
Credit Suisse first reported a position in Crescent Biopharma in Q2 2014 and held it in 10 quarters.
Credit Suisse's Crescent Biopharma position peaked at $1.34M in Q1 2018.
78 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2019.

Based on Credit Suisse's 13F filing for Q4 2019, filed 12 Feb 2020.